Sign Up to like & get
recommendations!
3
Published in 2023 at "Blood"
DOI: 10.1182/blood.2022017635
Abstract: Multiple myeloma (MM) is primarily a disease of elderly patients. Geriatric aspects in the context of MM have been poorly investigated until recently. Treatment outcomes for geriatric patients with MM are often compromised by comorbidities…
read more here.
Keywords:
treat multiple;
geriatric patient;
myeloma geriatric;
patient ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2020 at "Drugs of today"
DOI: 10.1358/dot.2020.56.7.3151521
Abstract: On October 29, 2019, the Food and Drug Administration (FDA) of the United States approved diroximel fumarate (DRF) as an oral fumarate for the treatment of relapsing forms of multiple sclerosis. Another oral fumarate, dimethyl…
read more here.
Keywords:
diroximel fumarate;
fumarate;
multiple sclerosis;
treat multiple ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Drugs of today"
DOI: 10.1358/dot.2021.57.12.3353166
Abstract: Ponesimod (ACT-128800) is a directly bioavailable, rapidly reversible sphingosine-1-phosphate (S1P) receptor modulator, highly selective for the subtype 1 (S1P₁ receptor). It acts by blocking the egress of lymphocytes from the lymphoid organs, thus limiting the…
read more here.
Keywords:
ponesimod;
treat multiple;
ponesimod treat;
multiple sclerosis ... See more keywords
Sign Up to like & get
recommendations!
2
Published in 2020 at "International Journal of Molecular Sciences"
DOI: 10.3390/ijms21218192
Abstract: Immunotherapy is increasingly used in the treatment of multiple myeloma (MM). Monoclonal antibodies (mAbs) are safe and effective ways to elicit immunotherapeutic responses. In 2015, daratumumab has become the first mAb approved by the Food…
read more here.
Keywords:
monoclonal antibodies;
multiple myeloma;
treat multiple;
antibodies treat ... See more keywords